VolitionRx Limited (NYSE American: VNRX) announced a breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA using its Capture-Seq platform. This advancement overcomes a longstanding challenge of distinguishing cancer DNA from healthy cell-free DNA in blood samples, potentially transforming early cancer detection and monitoring.
The company reported strong early validation results, including no false positives and successful detection across initial study cohorts. These findings support the potential of the technology as a novel biomarker approach for multi-cancer early detection and minimal residual disease monitoring. The combined total addressable market for these applications is approximately $36 billion, highlighting the significant commercial opportunity.
VolitionRx is actively engaging in discussions with global diagnostic and liquid biopsy companies to accelerate development and commercialization of the platform. The company's Capture-Seq technology is designed to isolate and analyze circulating tumor DNA with unprecedented purity, which could improve sensitivity and specificity in cancer screening and recurrence monitoring.
The breakthrough addresses a critical bottleneck in liquid biopsy: the difficulty of separating tumor-derived DNA from the abundant background of normal cell-free DNA. By achieving over 99% purity, VolitionRx's method enables more accurate detection of genetic mutations and epigenetic alterations associated with cancer. This could lead to earlier diagnosis, better treatment selection, and more effective monitoring of disease progression or recurrence.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, the company develops and commercializes simple, cost-effective blood tests to detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more information, visit the company's website at https://volition.com/.
To view the full press release, visit https://ibn.fm/1ZqGi.
